This segment focuses on the development of innovative cancer therapies using Silverback's proprietary ImmunoTAC technology. The lead product candidate, SBT6050, is currently in Phase I/Ib clinical trials, targeting HER2-expressing tumors such as breast, gastric, and non-small cell lung cancers. The research and development activities involve optimizing TLR8 agonist linker-payloads conjugated to tumor-directed monoclonal antibodies. The goal is to create systemically delivered, locally active therapies that stimulate the immune system within the tumor microenvironment, leading to improved patient outcomes. Future opportunities include expanding the pipeline to address other cancer types and exploring combination therapies with existing cancer treatments.

This segment is dedicated to developing therapies for chronic viral infections, with a primary focus on chronic hepatitis B virus (HBV) infection. The lead product candidate in this area is SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody. The research and development efforts are centered on designing targeted immunotherapies that can effectively clear the virus and restore immune control in chronically infected patients. The ImmunoTAC technology is leveraged to deliver TLR8 agonists specifically to infected cells, stimulating an antiviral immune response. Future opportunities include expanding the pipeline to address other chronic viral infections and exploring combination therapies with existing antiviral treatments.